Recombinant Human SERPINB9/PI-9 Protein (Human Cells, His Tag) | PKSH033318

Recombinant Human SERPINB9/PI-9 Protein (Human Cells, His Tag) | PKSH033318 | Gentaur US, UK & Europe Disrtribition

Synonyms: Cytoplasmic antiproteinase 3;Peptidase inhibitor 9;CAP3;PI-9;Serpin B9

Active Protein: N/A

Activity: Recombinant Human Serine Protease Inhibitor-clade B9 is produced by our Mammalian expression system and the target gene encoding Met1-Pro376 is expressed with a 6His tag at the C-terminus.

Protein Construction: Recombinant Human Serine Protease Inhibitor-clade B9 is produced by our Mammalian expression system and the target gene encoding Met1-Pro376 is expressed with a 6His tag at the C-terminus.

Fusion Tag: C-6His

Species: Human

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 95 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 43.4 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: Serpin B9; also known as Cytoplasmic antiproteinase 3(CAP-3); is a cytoplasm protein which belongs to the large superfamily of serine proteinase inhibitors (serpins); which bind to and inactivate serine proteinases. Serpin B9 is an inhibitor of the granzyme B/perforin lytic pathway. It is expressed in normal mammary epithelial cells but not in most mammary carcinoma cell lines. These interactions are involved in many cellular processes; including coagulation; fibrinolysis; complement fixation; matrix remodeling; and apoptosis. Serpin-B9 expression in immune-privileged cells; APCs; and CTLs protects these cells against the actions of granzyme B; and when expressed in tumor cells or virally infected hepatocytes; confers resistance to killing by CTL and NK cells. Expression of increasing levels of Serpin-B9 in target cells may progressively inhibit immune surveillance by blocking NK and CTL-induced cytotoxicity through the perforin / granzyme pathway and then through the Fas / FasL pathway.

Research Area: Cell biology, immunology